News Alector ditches GSK-partnered dementia drug and cuts staff Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.
News UK sets aside £2m for digitally-enhanced dementia tests The UK is providing £2m in funding to allow digital assessment to be added to a highly-anticipated trial of blood tests for diagnosing dementia.
News Astellas places $2bn+ bet on AviadoBio dementia gene therapy Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.